J&J profit beats Wall Street estimates
Johnson & Johnson’s first-quarter profit beat estimates as the health giant’s drug sales came in higher than Wall Street analysts expected.
Adjusted quarterly profit was US$2.71 a share, J&J said on Tuesday (Apr 16) in a statement, compared with analysts’ average estimate of US$2.65. Sales of medicines were US$13.6 billion, slightly outpacing the average estimate of analysts surveyed by Bloomberg, while overall revenue matched Wall Street projections.
J&J split off its consumer-health unit that makes Tylenol and Listerine last year in order to focus on higher-margin sales of drugs and medical devices. The company still faces declining revenues from its top-selling psoriasis drug Stelara next year, and is looking to products like prostate-cancer therapy Erleada and Tremfya for psoriasis to fill the gap.
New Brunswick, New Jersey-based J&J has also been investing in medical devices, agreeing earlier this month to buy Shockwave Medical for US$13.1 billion. J&J also closed the purchase of Abiomed, a maker of heart devices, at the end of 2022 for US$16.6 billion.
The company also slightly narrowed its adjusted profit guidance for the year to a range of US$10.57 to US$10.72 a share, from the earlier forecast of US$10.55 to US$10.75 a share. BLOOMBERG
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Yahoo to lay off staff in Singapore as it shifts to content curation
US: Wall St opens higher on megacap strength, Fed verdict awaited
IReit Global occupancy rate grows to 91.5% in Q1
Yen surges against US dollar on suspected intervention
GoTo narrows Q1 loss to 420 billion rupiah with TikTok deal, cost cuts
Asset manager Value Partners cuts one-third of China staff in overhaul: sources